Comparison of hematopoietic stem cell transplantation results in patients with beta-thalassemia major from three different graft types

Basit Öğe Kaydı
dc.contributor.authorAydoğdu, Selime
dc.contributor.authorToret, Ersin
dc.contributor.authorAksoy, Başak A.
dc.contributor.authorAydın, Muhammed Fatih
dc.contributor.authorCipe, Funda E.
dc.contributor.authorBozkurt, Ceyhun
dc.contributor.authorFışgın, Tunç
dc.date.accessioned2021-05-15T11:33:17Z
dc.date.available2021-05-15T11:33:17Z
dc.date.issued2021
dc.departmentTıp Fakültesi, Pediat Kemik İliği Nakil Ünitesien_US
dc.descriptionErol Cipe, Funda/0000-0002-9718-7507; Adakli Aksoy, Basak/0000-0001-8338-2101
dc.description.abstractAllogeneic hematopoietic stem cell transplantation (HSCT) is the curative therapy for beta-thalassemias that induces severe life-threatening complications. The human leukocyte antigen (HLA) registries and umbilical cord blood banks have carried out diligent searches to find matched unrelated donors (MUDs) for about 70.0% of patients from 2000 onwards. The chance of finding a non-sibling fully matched family donors is higher in some ethnic groups in which consanguineous marriages are common. We have studied and compared transplant complications and outcomes in different graft types (sibling, non-sibling family and unrelated). The non-sibling matched family donor (MFD) group consisted of four mothers, three fathers, five cousins, one paternal uncle and one paternal aunt. There was no significant difference in the mean transfused CD34+ cells, engraftment, median days of neutrophil and platelet recovery were achieved (p > 0.05). The distribution of postttransplant complication did not show any significant difference between groups (p > 0.05). In univariate analysis and multivarite analyses, age, gender, Pesaro risk group (I-II vs. III) and ABO incompatibilty demonstrated a significant difference in disease free survival (p < 0.05). Furthermore, in the second step of investigating overall survival (OS), age, gender and Pesaro risk group (I-II vs. III) showed a significant difference (p < 0.05). There was no significant difference in transplant-related mortality (TRM) between groups. Non-sibling related donor transplants are important for populations where consanguineous marriages are common. Transplant groups according to graft type had similar thalassemia-free survival (TFS) and OS when using a treosulfan-based regimen in our study.en_US
dc.identifier.doi10.1080/03630269.2021.1872611
dc.identifier.endpage29en_US
dc.identifier.issn0363-0269
dc.identifier.issn1532-432X
dc.identifier.issue1en_US
dc.identifier.pmid33478286
dc.identifier.scopus2-s2.0-85099909459
dc.identifier.scopusqualityQ3
dc.identifier.startpage25en_US
dc.identifier.urihttps://doi.org/10.1080/03630269.2021.1872611
dc.identifier.urihttps://hdl.handle.net/20.500.12939/122
dc.identifier.volume45en_US
dc.identifier.wosWOS:000611144500001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorFışgın, Tunç
dc.institutionauthorAydoğdu, Selime
dc.institutionauthorAydoğdu, Selime
dc.institutionauthorAksoy, Başak A.
dc.institutionauthorCipe, Funda E.
dc.institutionauthorAydın, Muhammed Fatih
dc.language.isoen
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofHemoglobin
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHematopoietic Stem Cell Transplantation (HSCT)en_US
dc.subjectNon-Sibling Family Donoren_US
dc.subjectPediatricsen_US
dc.subjectThalassemiaen_US
dc.subjectTreosulfanen_US
dc.titleComparison of hematopoietic stem cell transplantation results in patients with beta-thalassemia major from three different graft types
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu